Concepedia

Linda Y. Wu

LY

Statistics

Publications

17

Citations

754

H-Index

14

Active since

2017

Affiliations

National Yang Ming Chiao Tung University(Current)

Humanitas University

Imperial College London

Medical University of Vienna

Taipei Veterans General Hospital

Linda Y. Wu is an author at National Yang Ming Chiao Tung University specializing in oncology, medicine, and cancer immunotherapy.

ORCID

Publications per year

2017–2024

17

Publications

17

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida et al. · Hepatology · 2022 · 234 citations · Full text

, , +11

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio et al. · European Journal of Cancer · 2022 · 112 citations · Full text

, , +6

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Linda Y. Wu, Claudia Angela Maria Fulgenzi, Antonio D’Alessio et al. · Cancers · 2022 · 70 citations · Full text

, , +15

Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells

Linda Y. Wu, Uday Bhanu Maachani, Melanie Schweitzer et al. · Translational Oncology · 2017 · 65 citations · Full text

, , +17

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Mathew Vithayathil, Antonio D’Alessio, Claudia Angela Maria Fulgenzi et al. · Liver International · 2022 · 38 citations · Full text

, , +15

1–5 of 17